DYNE-101

DRUG3 trials

Sponsors

Dyne Therapeutics Inc., Dyne Therapeutics

Conditions

Myotonic Dystrophy Type 1Myotonic Dystrophy Type 1 (DM1)

Phase 1

Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1

RecruitingNCT05481879

Dyne TherapeuticsMyotonic Dystrophy Type 1 (DM1)

Start: 2022-09-05End: 2029-07-01Target: 116Updated: 2026-05-12

A Randomized, Placebo-Controlled, Multiple Ascending Dose Study Assessing Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics of DYNE-101 Administered to Participants with Myotonic Dystrophy Type 1

RecruitingCTIS2023-510353-42-00

Dyne Therapeutics Inc.Myotonic Dystrophy Type 1

Start: 2022-02-21Target: 93Updated: 2025-10-28

Phase 3

A Phase 3, Randomized, Double-Blind, 48-Week Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of DYNE-101 Administered to Participants with Myotonic Dystrophy Type 1

Not yet recruitingCTIS2025-522957-20-00

Dyne Therapeutics Inc.Myotonic Dystrophy Type 1

Target: 51Updated: 2026-04-29

Related Papers

Erythromycin for myotonic dystrophy type 1: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

2023-12-269 citations